Comparative proteomics, network analysis and post-translational modification identification reveal differential profiles of plasma Con A-bound glycoprotein biomarkers in gastric cancer

Journal of Proteomics

Volumn 83, Issue , 2013, Pages 197-213

  Uen, Yih Huei ^a,b,c   Lin, Kai Yuan ^b,d   Sun, Ding Ping ^b   Liao, Chen Chung ^e   Hsieh, Ming Song ^f,g,h   Huang, Yung Kai ^h   Chen, Yen Wei ⁱ   Huang, Pei Hsuan ^e   Chen, Wei Jung ^j   Tai, Chih Chun ^f   Lee, Kuan Wei ^h   Chen, You Chia ^h   Lin, Ching Yu ^h  

^a Chi Mei Hospital Chiali   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g Central Taiwan University   (Taiwan)

^h TAIPEI MEDICAL UNIVERSITY   (Taiwan)

ⁱ NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^j NATIONAL ILAN UNIVERSITY   (Taiwan)

more..

Author keywords

Concanavalin A; Gastric cancer; Glycoproteins; Human plasma; Mass spectrometry; Post translational modification

Indexed keywords

ALPHA 1B GLYCOPROTEIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; APOLIPOPROTEIN D; ASPARAGINE; ASPARTIC ACID; BIOLOGICAL MARKER; CLUSTERIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C5; CONCANAVALIN A; FIBRONECTIN; FLAVINE ADENINE NUCLEOTIDE; GLYCOPROTEIN; HEMOPEXIN; HEXOSE N ACETYL HEXOSAMINE; HISTIDINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN ALPHA 1 CHAIN C REGION; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN MU CHAIN; INTER ALPHA TRYPSIN INHIBITOR; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H3; LEUCINE RICH ALPHA 2 GLYCOPROTEIN; PLASMA PROTEASE C1 INHIBITOR; PLASMINOGEN; UNCLASSIFIED DRUG;

ACUTE PHASE RESPONSE; ADULT; AFFINITY CHROMATOGRAPHY; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GEL ELECTROPHORESIS; HEMATOPOIESIS; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METHYLATION; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEOMICS; SIGNAL TRANSDUCTION; STOMACH CANCER; UPREGULATION; WESTERN BLOTTING;

AGED; BLOOD PROTEINS; CHROMATOGRAPHY, AFFINITY; CONCANAVALIN A; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOME; PROTEOMICS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84876716480     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.03.007     Document Type: Article

References (109)

1. Tsugane S., Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 2007, 10:75-83.
2. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006, 118:3030-3044.
3. World Cancer Report 2003, IARC Press, Lyon. B.W.K.P. Stewart (Ed.).
4. Department of Health Cancer registry annual report, Taiwan 2004-2008.
5. Crew K.D., Neugut A.I. Epidemiology of gastric cancer. World J Gastroenterol 2006, 12:354-362.
6. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
7. Kim D.H., Oh S.J., Oh C.A., Choi M.G., Noh J.H., Sohn T.S., et al. The relationships between perioperative CEA, CA 19-9, and CA 72-4 and recurrence in gastric cancer patients after curative radical gastrectomy. J Surg Oncol 2011, 104:585-591.
8. Goodlett D.R., Keller A., Watts J.D., Newitt R., Yi E.C., Purvine S., et al. Differential stable isotope labeling of peptides for quantitation and de novo sequence derivation. Rapid Commun Mass Spectrom 2001, 15:1214-1221.
9. Heller M., Mattou H., Menzel C., Yao X. Trypsin catalyzed 16O-to-18O exchange for comparative proteomics: tandem mass spectrometry comparison using MALDI-TOF, ESI-QTOF, and ESI-ion trap mass spectrometers. J Am Soc Mass Spectrom 2003, 14:704-718.
10. Sechi S. A method to identify and simultaneously determine the relative quantities of proteins isolated by gel electrophoresis. Rapid Commun Mass Spectrom 2002, 16:1416-1424.
11. Kuyama H., Watanabe M., Toda C., Ando E., Tanaka K., Nishimura O. An approach to quantitative proteome analysis by labeling tryptophan residues. Rapid Commun Mass Spectrom 2003, 17:1642-1650.
12. Schmidt A., Kellermann J., Lottspeich F. A novel strategy for quantitative proteomics using isotope-coded protein labels. Proteomics 2005, 5:4-15.
13. Gygi S.P., Rist B., Gerber S.A., Turecek F., Gelb M.H., Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999, 17:994-999.
14. Ong S.E., Blagoev B., Kratchmarova I., Kristensen D.B., Steen H., Pandey A., et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002, 1:376-386.
15. Ross P.L., Huang Y.N., Marchese J.N., Williamson B., Parker K., Hattan S., et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004, 3:1154-1169.
16. Schulze W.X., Usadel B. Quantitation in mass-spectrometry-based proteomics. Annu Rev Plant Biol 2010, 61:491-516.
17. Old W.M., Meyer-Arendt K., Aveline-Wolf L., Pierce K.G., Mendoza A., Sevinsky J.R., et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 2005, 4:1487-1502.
18. Piersma S.R., Fiedler U., Span S., Lingnau A., Pham T.V., Hoffmann S., et al. Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum. J Proteome Res 2010, 9:1913-1922.
19. Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M. Proteomic characterization of the human centrosome by protein correlation profiling. Nature 2003, 426:570-574.
20. Matta A., Ralhan R., DeSouza L.V., Siu K.W. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery. Mass Spectrom Rev 2010, 29:945-961.
21. Karsdal M.A., Henriksen K., Leeming D.J., Woodworth T., Vassiliadis E., Bay-Jensen A.C. Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease?. Clin Biochem 2010, 43:793-804.
22. Anderson N.L. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010, 56:177-185.
23. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
24. Kovacech B., Novak M. Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease. Curr Alzheimer Res 2010, 7:708-716.
25. Guo H.B., Johnson H., Randolph M., Nagy T., Blalock R., Pierce M. Specific posttranslational modification regulates early events in mammary carcinoma formation. Proc Natl Acad Sci U S A 2010, 107:21116-21121.
26. Chen Y., Chen W., Cobb M.H., Zhao Y. PTMap-a sequence alignment software for unrestricted, accurate, and full-spectrum identification of post-translational modification sites. Proc Natl Acad Sci U S A 2009, 106:761-766.
27. Krueger K.E., Srivastava S. Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. Mol Cell Proteomics 2006, 5:1799-1810.
28. Zhang X.W., Yan X.J., Zhou Z.R., Yang F.F., Wu Z.Y., Sun H.B., et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010, 328:240-243.
29. Klose R.J., Yamane K., Bae Y., Zhang D., Erdjument-Bromage H., Tempst P., et al. The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature 2006, 442:312-316.
30. Vucic D., Dixit V.M., Wertz I.E. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 2011, 12:439-452.
31. McDonald C.A., Yang J.Y., Marathe V., Yen T.Y., Macher B.A. Combining results from lectin affinity chromatography and glycocapture approaches substantially improves the coverage of the glycoproteome. Mol Cell Proteomics 2009, 8:287-301.
32. Polanski M., Anderson N.L. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2007, 1:1-48.
33. Fung E.T. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 2010, 56:327-329.
34. OVA1™ Package Insert 2009.
35. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
36. Rajkumar R., Karthikeyan K., Archunan G., Huang P.H., Chen Y.W., Ng W.V., et al. Using mass spectrometry to detect buffalo salivary odorant-binding protein and its post-translational modifications. Rapid Commun Mass Spectrom 2010, 24:3248-3254.
37. Arnold K., Bordoli L., Kopp J., Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006, 22:195-201.
38. Schwede T., Kopp J., Guex N., Peitsch M.C. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 2003, 31:3381-3385.
39. Guex N., Peitsch M.C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997, 18:2714-2723.
40. Balasenthil S., Chen N., Lott S.T., Chen J., Carter J., Grizzle W.E., et al. A migration signature and plasma biomarker panel for pancreatic adenocarcinoma. Cancer Prev Res (Phila) 2011, 4:137-149.
41. Andersen J.D., Boylan K.L., Jemmerson R., Geller M.A., Misemer B., Harrington K.M., et al. Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients. J Ovarian Res 2010, 3:21.
42. He P., He H.Z., Dai J., Wang Y., Sheng Q.H., Zhou L.P., et al. The human plasma proteome: analysis of Chinese serum using shotgun strategy. Proteomics 2005, 5:3442-3453.
43. Li Y., Zhang Y., Qiu F., Qiu Z. Proteomic identification of exosomal LRG1: a potential urinary biomarker for detecting NSCLC. Electrophoresis 2011, 32:1976-1983.
44. Heo S.H., Lee S.J., Ryoo H.M., Park J.Y., Cho J.Y. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics 2007, 7:4292-4302.
45. Bourguignon J., Borghi H., Sesboue R., Diarra-Mehrpour M., Bernaudin J.F., Metayer J., et al. Immunohistochemical distribution of inter-alpha-trypsin inhibitor chains in normal and malignant human lung tissue. J Histochem Cytochem 1999, 47:1625-1632.
46. Jha R.K., Ma Q., Chen S., Sha H., Ding S. Relationship of fibronectin and CD44v6 expression with invasive growth and metastasis of liver cancer. Cancer Invest 2009, 27:324-328.
47. Kakisaka T., Kondo T., Okano T., Fujii K., Honda K., Endo M., et al. Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 852:257-267.
48. Zhao J., Patwa T.H., Qiu W., Shedden K., Hinderer R., Misek D.E., et al. Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. J Proteome Res 2007, 6:1864-1874.
49. Linden M., Lind S.B., Mayrhofer C., Segersten U., Wester K., Lyutvinskiy Y., et al. Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer. Proteomics 2012, 12:135-144.
50. Sandanayake N.S., Sinclair J., Andreola F., Chapman M.H., Xue A., Webster G.J., et al. A combination of serum leucine-rich alpha-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures. Br J Cancer 2011, 105:1370-1378.
51. Mazouni C., Baggerly K., Hawke D., Tsavachidis S., Andre F., Buzdar A.U., et al. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure. Proteomics 2010, 10:3525-3532.
52. Zeng Z., Hincapie M., Pitteri S.J., Hanash S., Schalkwijk J., Hogan J.M., et al. A proteomics platform combining depletion, multi-lectin affinity chromatography (M-LAC), and isoelectric focusing to study the breast cancer proteome. Anal Chem 2011, 83:4845-4854.
53. Liang S., Singh M., Dharmaraj S., Gam L.H. The PCA and LDA analysis on the differential expression of proteins in breast cancer. Dis Markers 2010, 29:231-242.
54. Hamm A., Veeck J., Bektas N., Wild P.J., Hartmann A., Heindrichs U., et al. Frequent expression loss of inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis. BMC Cancer 2008, 8:25.
55. Cho W., Jung K., Regnier F.E. Sialylated Lewis×antigen bearing glycoproteins in human plasma. J Proteome Res 2010, 9:5960-5968.
56. Seriramalu R., Pang W.W., Jayapalan J.J., Mohamed E., Abdul-Rahman P.S., Bustam A.Z., et al. Application of champedak mannose-binding lectin in the glycoproteomic profiling of serum samples unmasks reduced expression of alpha-2 macroglobulin and complement factor B in patients with nasopharyngeal carcinoma. Electrophoresis 2010, 31:2388-2395.
57. Waalkes S., Atschekzei F., Kramer M.W., Hennenlotter J., Vetter G., Becker J.U., et al. Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer 2010, 10:503.
58. Wilson C. Cancer: oncofetal fibronectin mRNA and papillary thyroid cancer. Nat Rev Endocrinol 2010, 6:475.
59. Wei P.L., Kuo L.J., Huang M.T., Ting W.C., Ho Y.S., Wang W., et al. Nicotine enhances colon cancer cell migration by induction of fibronectin. Ann Surg Oncol 2011, 18:1782-1790.
60. Beecken W.D., Bentas W., Engels K., Glienke W., Urbschat A., Jonas D., et al. Reduced plasma levels of coagulation factors in relation to prostate cancer. Prostate 2002, 53:160-167.
61. Seal U.S., Doe R.P., Byar D.P., Corle D.K. Response of plasma fibrinogen and plasminogen to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer. Cancer 1976, 38:1108-1117.
62. Miranda E., Vizoso F., Martin A., Quintela I., Corte M.D., Segui M.E., et al. Apolipoprotein D expression in cutaneous malignant melanoma. J Surg Oncol 2003, 83:99-105.
63. Luo Y., Robinson S., Fujita J., Siconolfi L., Magidson J., Edwards C.K., et al. Transcriptome profiling of whole blood cells identifies PLEK2 and C1QB in human melanoma. PLoS One 2011, 6:e20971.
64. Josic D., Brown M.K., Huang F., Lim Y.P., Rucevic M., Clifton J.G., et al. Proteomic characterization of inter-alpha inhibitor proteins from human plasma. Proteomics 2006, 6:2874-2885.
65. Liu T., Qian W.J., Gritsenko M.A., Camp D.G., Monroe M.E., Moore R.J., et al. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. J Proteome Res 2005, 4:2070-2080.
66. Nilsson J., Ruetschi U., Halim A., Hesse C., Carlsohn E., Brinkmalm G., et al. Enrichment of glycopeptides for glycan structure and attachment site identification. Nat Methods 2009, 6:809-811.
67. Enghild J.J., Salvesen G., Hefta S.A., Thogersen I.B., Rutherfurd S., Pizzo S.V. Chondroitin 4-sulfate covalently cross-links the chains of the human blood protein pre-alpha-inhibitor. J Biol Chem 1991, 266:747-751.
68. Sturgeon C.M., Duffy M.J., Hofmann B.R., Lamerz R., Fritsche H.A., Gaarenstroom K., et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010, 56:e1-e48.
69. Bones J., Mittermayr S., O'Donoghue N., Guttman A., Rudd P.M. Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation. Anal Chem 2010, 82:10208-10215.
70. Xu Y., Zhang L., Hu G. Potential application of alternatively glycosylated serum MUC1 and MUC5AC in gastric cancer diagnosis. Biologicals 2009, 37:18-25.
71. Klaamas K., Kodar K., Kurtenkov O. An increased level of the Concanavalin A-positive IgG in the serum of patients with gastric cancer as evaluated by a lectin enzyme-linked immunosorbent assay (LELISA). Neoplasma 2008, 55:143-150.
72. Bones J., Byrne J.C., O'Donoghue N., McManus C., Scaife C., Boissin H., et al. Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J Proteome Res 2011, 10:1246-1265.
73. Gautier V., Mouton-Barbosa E., Bouyssie D., Delcourt N., Beau M., Girard J.P., et al. Label-free quantification and shotgun analysis of complex proteomes by one-dimensional SDS-PAGE/NanoLC-MS: evaluation for the large scale analysis of inflammatory human endothelial cells. Mol Cell Proteomics 2012, 11:527-539.
74. Maley F., Trimble R.B., Tarentino A.L., Plummer T.H. Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases. Anal Biochem 1989, 180:195-204.
75. Koutroukides T.A., Guest P.C., Leweke F.M., Bailey D.M., Rahmoune H., Bahn S., et al. Characterization of the human serum depletome by label-free shotgun proteomics. J Sep Sci 2011, 34:1621-1626.
76. Kim CW OS, Han MY, Shin YS. Protein markers for diagnosing stomach cancer and the diagnostic kit using them. USPTO Issued patent, US7892761. 2011.
77. Andersen J.D., Boylan K.L., Xue F.S., Anderson L.B., Witthuhn B.A., Markowski T.W., et al. Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. Electrophoresis 2010, 31:599-610.
78. Okano T., Kondo T., Kakisaka T., Fujii K., Yamada M., Kato H., et al. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 2006, 6:3938-3948.
79. Lin C.P., Chen Y.W., Liu W.H., Chou H.C., Chang Y.P., Lin S.T., et al. Proteomic identification of plasma biomarkers in uterine leiomyoma. Mol BioSyst 2012, 8:1136-1145.
80. Weivoda S., Andersen J.D., Skogen A., Schlievert P.M., Fontana D., Schacker T., et al. ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand. J Immunol Methods 2008, 336:22-29.
81. Serada S., Fujimoto M., Ogata A., Terabe F., Hirano T., Iijima H., et al. iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Ann Rheum Dis 2010, 69:770-774.
82. Watson C.J., Ledwidge M.T., Phelan D., Collier P., Byrne J.C., Dunn M.J., et al. Proteomic analysis of coronary sinus serum reveals leucine-rich alpha2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure. Circ Heart Fail 2011, 4:188-197.
83. Wang H., Clouthier S.G., Galchev V., Misek D.E., Duffner U., Min C.K., et al. Intact-protein-based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics 2005, 4:618-625.
84. Dai L., Liu Y., He J., Flack C.G., Talsma C.E., Crowley J.G., et al. Differential profiling studies of N-linked glycoproteins in glioblastoma cancer stem cells upon treatment with gamma-secretase inhibitor. Proteomics 2011, 11:4021-4028.
85. Linden M., Lind S.B., Mayrhofer C., Segersten U., Wester K., Lyutvinskiy Y., et al. Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer. Proteomics 2012, 12:135-144.
86. Bella J., Hindle K.L., McEwan P.A., Lovell S.C. The leucine-rich repeat structure. Cell Mol Life Sci 2008, 65:2307-2333.
87. Shirai R., Hirano F., Ohkura N., Ikeda K., Inoue S. Up-regulation of the expression of leucine-rich alpha(2)-glycoprotein in hepatocytes by the mediators of acute-phase response. Biochem Biophys Res Commun 2009, 382:776-779.
88. Himmelfarb M., Klopocki E., Grube S., Staub E., Klaman I., Hinzmann B., et al. ITIH5, a novel member of the inter-alpha-trypsin inhibitor heavy chain family is downregulated in breast cancer. Cancer Lett 2004, 204:69-77.
89. Paris S., Sesboue R., Delpech B., Chauzy C., Thiberville L., Martin J.P., et al. Inhibition of tumor growth and metastatic spreading by overexpression of inter-alpha-trypsin inhibitor family chains. Int J Cancer 2002, 97:615-620.
90. Chong P.K., Lee H., Zhou J., Liu S.C., Loh M.C., Wang T.T., et al. ITIH3 is a potential biomarker for early detection of gastric cancer. J Proteome Res 2010, 9:3671-3679.
91. Baldwin E.T., Sarver R.W., Bryant G.L., Curry K.A., Fairbanks M.B., Finzel B.C., et al. Cation binding to the integrin CD11b I domain and activation model assessment. Structure 1998, 6:923-935.
92. Colombatti A., Bonaldo P. The superfamily of proteins with von Willebrand factor type A-like domains: one theme common to components of extracellular matrix, hemostasis, cellular adhesion, and defense mechanisms. Blood 1991, 77:2305-2315.
93. Enghild J.J., Salvesen G., Thogersen I.B., Valnickova Z., Pizzo S.V., Hefta S.A. Presence of the protein-glycosaminoglycan-protein covalent cross-link in the inter-alpha-inhibitor-related proteinase inhibitor heavy chain 2/bikunin. J Biol Chem 1993, 268:8711-8716.
94. Lee J.O., Rieu P., Arnaout M.A., Liddington R. Crystal structure of the A domain from the alpha subunit of integrin CR3 (CD11b/CD18). Cell 1995, 80:631-638.
95. Bajt M.L., Loftus J.C. Mutation of a ligand binding domain of beta 3 integrin. Integral role of oxygenated residues in alpha IIb beta 3 (GPIIb-IIIa) receptor function. J Biol Chem 1994, 269:20913-20919.
96. Kondo Y., Shen L., Cheng A.S., Ahmed S., Boumber Y., Charo C., et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008, 40:741-750.
97. Schneider A.C., Heukamp L.C., Rogenhofer S., Fechner G., Bastian P.J., von Ruecker A., et al. Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer. BJU Int 2011, 108:E290-E296.
98. Zhang L., Zhong K., Dai Y., Zhou H. Genome-wide analysis of histone H3 lysine 27 trimethylation by ChIP-chip in gastric cancer patients. J Gastroenterol 2009, 44:305-312.
99. Li Q., Wang X., Lu Z., Zhang B., Guan Z., Liu Z., et al. Polycomb CBX7 directly controls trimethylation of histone H3 at lysine 9 at the p16 locus. PLoS One 2010, 5:e13732.
100. Huq M.D., Tsai N.P., Khan S.A., Wei L.N. Lysine trimethylation of retinoic acid receptor-alpha: a novel means to regulate receptor function. Mol Cell Proteomics 2007, 6:677-688.
101. Werner R., Manthey K.C., Griffin J.B., Zempleni J. HepG2 cells develop signs of riboflavin deficiency within 4days of culture in riboflavin-deficient medium. J Nutr Biochem 2005, 16:617-624.
102. Pinto J., Huang Y.P., Chaudhuri R., Rivlin R.S. Disturbances in the formation of FAD and covalently bound flavins in Novikoff hepatoma from riboflavin-deficient rats. Nutr Cancer 1987, 10:95-102.
103. Koturbash I., Simpson N.E., Beland F.A., Pogribny I.P. Alterations in histone H4 lysine 20 methylation: implications for cancer detection and prevention. Antioxid Redox Signal 2012, 17:365-374.
104. Wada Y., Ito M., Takata S., Tanaka S., Yoshihara M., Chayama K. Relationship between Helicobacter pylori tyrosine-phosphorylated CagA-related markers and the development of diffuse-type gastric cancers: a case-control study. Digestion 2010, 82:10-17.
105. Chang X., Han J., Pang L., Zhao Y., Yang Y., Shen Z. Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer 2009, 9:40.
106. Oya-Ito T., Naito Y., Takagi T., Handa O., Matsui H., Yamada M., et al. Heat-shock protein 27 (Hsp27) as a target of methylglyoxal in gastrointestinal cancer. Biochim Biophys Acta 1812, 2011:769-781.
107. Sugiura T. The cellular level of TRIM31, an RBCC protein overexpressed in gastric cancer, is regulated by multiple mechanisms including the ubiquitin-proteasome system. Cell Biol Int 2011, 35:657-661.
108. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
109. Ikeguchi M., Hatada T., Yamamoto M., Miyake T., Matsunaga T., Fukumoto Y., et al. Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer 2009, 12:95-100.